Department of Neurological Surgery, University of Kansas Medical Center, 3901 Rainbow Blvd # MS 3021, Kansas City, KS, USA.
Department of Neurological Surgery, University of Miami, Miami, FL, USA.
Acta Neurol Belg. 2023 Dec;123(6):2077-2084. doi: 10.1007/s13760-022-02169-8. Epub 2023 Jan 3.
The goal of this study was to systematically review the metabolic profile of meningiomas using magnetic resonance spectroscopy in comparison to gliomas, as measured by mean metabolite ratios.
Following the PRISMA guidelines, a systematic literature review was performed using the PubMed, Ovid Embase, Web of Science, and the Cochrane databases from inception to May 2021. Studies were selected based on predetermined inclusion and exclusion criteria.
Eight studies were ultimately selected with 207 patients included. Fifty-nine patients were diagnosed with meningioma (age = 48.4, 66.7% female) and 148 patients diagnosed with glioma (age = 56.4, 49.2% female). Three studies reported elevated Cho/Cr in meningiomas compared to gliomas (5.71 vs. 1.46, p < 0.05, 7.02 vs. 2.62, p < 0.05, and 4.64 vs. 2.52, p = 0.001). One study reported Ala/Cr to be significantly elevated in meningiomas compared to gliomas (1.30 vs. undetectable, p < 0.001). One study reported myo-Inositol/Cr to be significantly elevated in meningiomas in comparison to gliomas (1.44 vs. 1.08, p < 0.05). One study reported Glu/Cr to be significantly elevated in meningiomas in comparison to gliomas (3.47 vs. 0.89, p = 0.002). Two studies reported Cho/NAA to be significantly elevated in meningiomas in comparison to gliomas (4.46 vs. 2.6, p = 0.004, and 5.8 vs. 2.55, p < 0.05). Two studies reported NAA/Cr was significantly elevated in gliomas compared to meningiomas (undetectable vs. 1.54, p < 0.001 and undetectable vs. 0.58, p < 0.05).
Significant differences in metabolite ratios between tumor types were reported in Cho/Cr, Ala/Cr, Glu/Cr, Cho/NAA, myoI/Cr and NAA/Cr between meningiomas and gliomas.
本研究旨在通过磁共振波谱（MRS）测量的平均代谢物比值，系统地比较脑膜瘤和胶质瘤的代谢谱。
根据 PRISMA 指南，我们使用 PubMed、Ovid Embase、Web of Science 和 Cochrane 数据库，从建库至 2021 年 5 月进行了系统的文献回顾。研究根据预先确定的纳入和排除标准进行选择。
最终纳入 8 项研究，共 207 例患者。59 例患者被诊断为脑膜瘤（年龄=48.4，66.7%为女性），148 例患者被诊断为胶质瘤（年龄=56.4，49.2%为女性）。3 项研究报告脑膜瘤的 Cho/Cr 比值高于胶质瘤（5.71 比 1.46，p<0.05，7.02 比 2.62，p<0.05，和 4.64 比 2.52，p=0.001）。1 项研究报告脑膜瘤的 Ala/Cr 比值明显高于胶质瘤（1.30 比不可检测，p<0.001）。1 项研究报告脑膜瘤的肌醇/Cr 比值明显高于胶质瘤（1.44 比 1.08，p<0.05）。1 项研究报告脑膜瘤的 Glu/Cr 比值明显高于胶质瘤（3.47 比 0.89，p=0.002）。2 项研究报告脑膜瘤的 Cho/NAA 比值明显高于胶质瘤（4.46 比 2.6，p=0.004，和 5.8 比 2.55，p<0.05）。2 项研究报告胶质瘤的 NAA/Cr 比值明显高于脑膜瘤（不可检测比 1.54，p<0.001，和不可检测比 0.58，p<0.05）。
脑膜瘤和胶质瘤之间在 Cho/Cr、Ala/Cr、Glu/Cr、Cho/NAA、肌醇/Cr 和 NAA/Cr 等代谢物比值方面存在显著差异。
